GUOTAI HAITONG SECURITIES·2025-11-10 07:49Investment Rating - The investment rating for the company is "Accumulate" with a target price of 39.59 CNY [5][10]. Core Insights - The company's performance is under short-term pressure, but new orders are improving, indicating potential for recovery in profitability [2][10]. - The overall order backlog as of Q1-Q3 2025 is 2.5 billion CNY, with new orders amounting to 1.64 billion CNY, reflecting a year-on-year increase of 17.1% [10]. - The company is focusing on expanding its client base, particularly large clients, with significant increases in project signings in various therapeutic areas [10]. Financial Summary - Total revenue for 2023 is projected at 2,376 million CNY, with a decline to 1,525 million CNY in 2025, representing a 24.4% decrease [3][11]. - Net profit attributable to shareholders is expected to drop significantly from 397 million CNY in 2023 to 121 million CNY in 2025, a decrease of 63.0% [3][11]. - Earnings per share (EPS) is forecasted to be 0.16 CNY in 2025, down from 0.53 CNY in 2023 [3][11]. Order Trends - The company has seen a positive trend in new orders, with Q3 2025 alone contributing approximately 620 million CNY in new contracts, a 24.0% increase year-on-year [10]. - The signing of antibody projects has increased by 20%, and projects in small nucleic acids and ADCs have seen over a 50% increase in signings [10]. Capacity and Quality Improvements - The company is steadily advancing its capacity, with new facilities in Suzhou and Guangzhou nearing completion [10]. - The company has successfully passed FDA GLP inspections, enhancing its competitive position in the industry [10].